Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.65 |
| ▸ | RET | P07949 | 12/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016201 | 0.83 | ADORA1 (0.68) | ADORA1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL6462280 | 0.82 | ADORA1 (0.63) | ADORA1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL7018471 | 0.82 | RET (0.58) | ADORA1RETABL1ALKPDE3A | |
| SCHEMBL6466193 | 0.79 | ADORA1 (0.60) | ADORA1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL26632985 | 0.78 | ADORA1 (0.61) | ADORA1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL7019128 | 0.76 | ALDH1A1 (0.79) | ADORA1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL1421425 | 0.76 | ADORA1 (0.56) | ADORA1PDE3AALDH1A1HSD17B10 | |
| SCHEMBL3549098 | 0.75 | ADORA1 (0.72) | ADORA1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL1421834 | 0.74 | KDM4E (0.62) | ADORA1ALDH1A1HSD17B10 | |
| SCHEMBL6440940 | 0.73 | HSD17B10 (0.62) | ADORA1ALDH1A1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | ADORA1 1628/4885RET 2565/4885ABL1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.